Treatment of severe lupus nephritis: the new horizon
- PMID:25421826
- DOI: 10.1038/nrneph.2014.215
Treatment of severe lupus nephritis: the new horizon
Abstract
Lupus nephritis is a common and severe manifestation of systemic lupus erythematosus, and an important cause of both acute kidney injury and end-stage renal disease. Despite its aggressive course, lupus nephritis is amenable to treatment in the majority of patients. The paradigm of immunosuppressive treatment for lupus nephritis has evolved over the past few decades from corticosteroids alone to corticosteroids combined with cyclophosphamide. Sequential treatment regimens using various agents have been formulated for induction and long-term maintenance therapy, and mycophenolate mofetil has emerged as a standard of care option for both induction and maintenance immunosuppressive treatment. The current era has witnessed the emergence of multiple novel therapeutic options, such as calcineurin inhibitors and biologic agents that target key pathogenetic mechanisms of lupus nephritis. Clinical outcomes have improved in parallel with these therapeutic advances. This Review discusses the evidence in support of current standard of care immunosuppressive treatments and emerging therapies, and describes their roles and relative merits in the management of patients with lupus nephritis.
Similar articles
- Sequential therapies for proliferative lupus nephritis.Contreras G, Pardo V, Leclercq B, Lenz O, Tozman E, O'Nan P, Roth D.Contreras G, et al.N Engl J Med. 2004 Mar 4;350(10):971-80. doi: 10.1056/NEJMoa031855.N Engl J Med. 2004.PMID:14999109Clinical Trial.
- Combined immunosuppressive treatment (CIST) in lupus nephritis: a multicenter, randomized controlled study.An Y, Zhou Y, Bi L, Liu B, Wang H, Lin J, Xu D, Wang M, Zhang J, Wang Y, An Y, Zhu P, Xie R, Zhang Z, Mei Y, Liu X, Deng X, Yao Z, Zhang Z, Wang Y, Xiao W, Shen H, Yang X, Xu H, Yu F, Wang G, Lu X, Li Y, Li Y, Zuo X, Li Y, Liu Y, Zhao Y, Guo J, Sun L, Zhao M, Li Z.An Y, et al.Clin Rheumatol. 2019 Apr;38(4):1047-1054. doi: 10.1007/s10067-018-4368-8. Epub 2018 Nov 28.Clin Rheumatol. 2019.PMID:30488367Clinical Trial.
- Treatment options for severe lupus nephritis.Lenz O, Contreras G.Lenz O, et al.Arch Immunol Ther Exp (Warsz). 2004 Sep-Oct;52(5):356-65.Arch Immunol Ther Exp (Warsz). 2004.PMID:15507877Review.
- Mycophenolate mofetil for lupus nephritis: an update.Mok CC.Mok CC.Expert Rev Clin Immunol. 2015;11(12):1353-64. doi: 10.1586/1744666X.2015.1087314. Epub 2015 Sep 12.Expert Rev Clin Immunol. 2015.PMID:26364748Review.
- Maintenance therapies for proliferative lupus nephritis: mycophenolate mofetil, azathioprine and intravenous cyclophosphamide.Contreras G, Tozman E, Nahar N, Metz D.Contreras G, et al.Lupus. 2005;14 Suppl 1:s33-8. doi: 10.1191/0961203305lu2115oa.Lupus. 2005.PMID:15803929Clinical Trial.
Cited by
- Single cell RNA sequencing to dissect the molecular heterogeneity in lupus nephritis.Der E, Ranabothu S, Suryawanshi H, Akat KM, Clancy R, Morozov P, Kustagi M, Czuppa M, Izmirly P, Belmont HM, Wang T, Jordan N, Bornkamp N, Nwaukoni J, Martinez J, Goilav B, Buyon JP, Tuschl T, Putterman C.Der E, et al.JCI Insight. 2017 May 4;2(9):e93009. doi: 10.1172/jci.insight.93009. eCollection 2017 May 4.JCI Insight. 2017.PMID:28469080Free PMC article.
- Clinical research progress of novel biologics for the treatment of lupus nephritis.Cui W, Tian Y, Huang G, Zhang X, Li F, Liu X.Cui W, et al.Clin Exp Med. 2023 Dec;23(8):4153-4162. doi: 10.1007/s10238-023-01143-9. Epub 2023 Jul 22.Clin Exp Med. 2023.PMID:37481481Review.
- GBP2 acts as a member of the interferon signalling pathway in lupus nephritis.Zhang Y, Liao Y, Hang Q, Sun D, Liu Y.Zhang Y, et al.BMC Immunol. 2022 Sep 17;23(1):44. doi: 10.1186/s12865-022-00520-5.BMC Immunol. 2022.PMID:36115937Free PMC article.
- First Real-World Insights into Belimumab Use and Outcomes in Routine Clinical Care of Systemic Lupus Erythematosus in Germany: Results from the OBSErve Germany Study.Schwarting A, Schroeder JO, Alexander T, Schmalzing M, Fiehn C, Specker C, Perna A, Cholmakow-Bodechtel C, Koscielny VB, Carnarius H.Schwarting A, et al.Rheumatol Ther. 2016 Dec;3(2):271-290. doi: 10.1007/s40744-016-0047-x. Epub 2016 Nov 1.Rheumatol Ther. 2016.PMID:27804088Free PMC article.
- Lupus Nephritis in Asia: Clinical Features and Management.Yap DY, Chan TM.Yap DY, et al.Kidney Dis (Basel). 2015 Sep;1(2):100-9. doi: 10.1159/000430458. Epub 2015 Aug 5.Kidney Dis (Basel). 2015.PMID:27536670Free PMC article.Review.
References
Publication types
MeSH terms
Substances
Related information
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous